Oncolys BioPharma Inc. | Income Statement
Fiscal year is January-December. All values JPY Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
1,180.00
28,797.00
121,303.00
178,313.00
229,139.00
168,549
Cost of Goods Sold (COGS) incl. D&A
17,179.00
16,137.00
17,138.00
15,738.00
71,557.00
121,331
Gross Income
15,999.00
12,660.00
104,165.00
162,575.00
157,582.00
47,218
SG&A Expense
649,463.00
840,404.00
927,699.00
1,023,886.00
1,169,656.00
1,231,224
EBIT
665,462.00
827,744.00
823,534.00
861,311.00
1,078,388.00
1,247,563
Unusual Expense
7,891.00
11,023.00
-
64,223.00
-
-
Non Operating Income/Expense
42,116.00
103,698.00
97,531.00
4,482.00
9,408.00
1,126
Interest Expense
2,839.00
4,943.00
4,244.00
3,221.00
3,274.00
2,797
Pretax Income
633,193.00
737,106.00
854,701.00
928,344.00
1,087,185.00
1,230,105
Income Tax
2,360.00
1,893.00
2,589.00
3,052.00
3,518.00
3,740
Consolidated Net Income
635,553.00
738,999.00
857,290.00
931,397.00
1,090,703.00
1,233,846
Net Income
635,553.00
738,999.00
857,290.00
931,397.00
1,090,703.00
1,233,846
Net Income After Extraordinaries
635,553.00
738,999.00
857,290.00
931,397.00
1,090,703.00
1,233,846
Net Income Available to Common
635,553.00
738,999.00
857,290.00
931,397.00
1,090,703.00
1,233,846
EPS (Basic)
94.33
80.55
93.35
101.18
106.23
104.55
Basic Shares Outstanding
6,737.40
9,174.40
9,183.60
9,205.60
10,267.10
11,801.80
EPS (Diluted)
94.33
80.55
93.35
101.18
106.23
104.55
Diluted Shares Outstanding
6,737.40
9,174.40
9,183.60
9,205.60
10,267.10
11,801.80
EBITDA
648,323.00
811,859.00
806,412.00
845,589.00
1,076,868.00
1,245,496
Other Operating Expense
-
-
-
-
66,314.00
63,557
Non-Operating Interest Income
883.00
2,906.00
3,587.00
4,894.00
3,887.00
21,380
About Oncolys BioPharma
View Profile
